Alto Neuroscience, Inc. announced multiple presentations at the Society of Biological Psychiatry (SOBP) Annual Meeting, showcasing new data that supports its precision psychiatry pipeline. The company successfully identified and prospectively replicated an EEG-based biomarker for placebo response in Major Depressive Disorder (MDD).
Further data strengthened the mechanistic link between ALTO-300 and its machine-learning derived EEG biomarker, which is used for patient selection. This research demonstrated that increasing 5-HT2C activity or directly depleting dopamine, both opposite effects of ALTO-300, resulted in greater EEG irregularity consistent with a biomarker-positive profile.
Additionally, a preclinical rescue study for ALTO-101 demonstrated an increase in theta response, validating it as a robust translational biomarker for Cognitive Impairment Associated with Schizophrenia (CIAS). These findings reinforce Alto's strategy to leverage objective biomarkers for targeted neuropsychiatric drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.